A Phase 1/2 interventional study of Elacestrant and Onapristone in Breast Cancer, sponsored by Context Therapeutics Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Context Therapeutics Inc. · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
This is a multicenter, phase 1b-2 trial. The phase 1b part of the trial is open label and aims to determine the recommended Phase 2 dose (RP2D) of onapristone and elacestrant when administered together. The Phase 2 part of the trial will evaluate the efficacy and safety of this combination in patients with ER+/PgR+/HER2- advanced/metastatic breast cancer after prior therapy with a CDK4/6 inhibitor.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
This study's enrollment of 4 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Context Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has adequate bone marrow and organ function, as defined by the following laboratory values:
Exclusion Criteria:
Uncontrolled significant active infections.
Females of who:
Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elacestrant and Onapristone combination
Drug: Elacestrant · Drug: Onapristone
Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.
Also known as: RAD1901
Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.
Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle
DLTs were pre-specified toxicities occurring during Cycle 1 (28 days) and considered at least possibly related to study treatment, based on CTCAE criteria. Assessment of safety and tolerability to determine the recommended Phase 2 dose (RP2D). DLT defined as dose associated with \<33% of patients experiencing DLT (≤1 patient out of 6 DLT-evaluable patients).
Time frame: First 28 days (Cycle 1)
Objective Response Rate (ORR)
ORR was defined as the proportion of patients achieving confirmed complete or partial response per RECIST v1.1; Phase 2 was not initiated, and no patients were enrolled.
Time frame: Assessed every 8 weeks until disease progression, up to approximately 6 months
Adverse Events (AEs)
Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of AEs was collected.
Time frame: From first dose until 30 days after last dose (up to 183 days)
Serious Adverse Events (SAEs)
Serious Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of SAEs was collected
Time frame: 183 days
Evaluate the Maximum Plasma Concentration (Cmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1)
AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients
Time frame: 15 Days
Evaluate the Time of the Maximum Observed Plasma Concentration (Tmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1).
AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients
Time frame: 15 Days
Evaluate Duration of Response
Time from first CR/PR until progression or death
Time frame: From first documented CR/PR until progression or death, up to 183 days
Evaluate Clinical Benefit Rate
Proportion of subjects achieving a best overall or complete response, or durable stable disease (duration is at least 23 weeks)
Time frame: 183 days
Evaluate Progression-free Survival
Time from the date of the first dose to the date of the first documentation of disease progression or death, whichever occurs first.
Time frame: 183 Days
Five patients were screened and four were enrolled into Phase 1b Cohort 1 at three U.S. sites.
| Milestone | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 |
|---|---|---|---|---|
| Started | 4 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 4 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 | 0 |
DLTs were pre-specified toxicities occurring during Cycle 1 (28 days) and considered at least possibly related to study treatment, based on CTCAE criteria. Assessment of safety and tolerability to determine the recommended Phase 2 dose (RP2D). DLT defined as dose associated with \<33% of patients experiencing DLT (≤1 patient out of 6 DLT-evaluable patients).
| Participants | Elacestrant / Onapristone |
|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle | 1 |
Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of AEs was collected.
| Participants | Elacestrant / Onapristone |
|---|---|
| Adverse Events (AEs) | 3 |
Serious Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of SAEs was collected
| Participants | Elacestrant / Onapristone |
|---|---|
| Serious Adverse Events (SAEs) | 0 |
AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients
| ng/mL | Onapristone Pharmacokinetics | Desmethyl Onapristone (Metabolite) Pharmacokinetics |
|---|---|---|
| Patient 1 | 2,250 | 70.2 |
| Patient 2 | 1,260 | 42.0 |
AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients
| hours | Onapristone Pharmacokinetics Tmax |
|---|---|
| Patient 1 | 6 |
| Patient 2 | 6 |
Time from first CR/PR until progression or death
| Participants | Elacestrant / Onapristone |
|---|---|
| Evaluate Duration of Response | 0 |
ORR was defined as the proportion of patients achieving confirmed complete or partial response per RECIST v1.1; Phase 2 was not initiated, and no patients were enrolled.
| Participants | Elacestrant / Onapristone |
|---|---|
| Objective Response Rate (ORR) | 0 |
Proportion of subjects achieving a best overall or complete response, or durable stable disease (duration is at least 23 weeks)
| Participants | Response Category |
|---|---|
| Stable Disease (SD) | 1 |
| Progressive Disease | 3 |
Time from the date of the first dose to the date of the first documentation of disease progression or death, whichever occurs first.
| Days | Elacestrant / Onapristone |
|---|---|
| Evaluate Progression-free Survival | 85 (55 to 115) |
Collected over From first dose until 30 days after last dose (up to 183 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Cohort 1 |
|---|---|
| FatigueGeneral disorders | 1/4 |
| Urinary tract infectionInfections and infestations | 1/4 |
| Blood cholesterol increasedInvestigations | 1/4 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/4 |
| InsomniaPsychiatric disorders | 1/4 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 1/4 |
| Age, Categorical(Participants) | Cohort 1 |
|---|---|
| <=18 years | 4 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Cohort 1 |
|---|---|
| Female | 4 |
| Male | 0 |
| Race and Ethnicity Not Collected(Participants) | Cohort 1 |
|---|
| Breast Cancer Subtype(Participants) | Cohort 1 |
|---|---|
| Count of participants | 4 |
| Disease Status(Participants) | Cohort 1 |
|---|---|
| Count of participants | 4 |
| ECOG Performance Status(Participants) | Cohort 1 |
|---|---|
| Count of participants | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Jun 2023, 6 months.
Results were first posted in Jul 2026, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Onapristone
Context Therapeutics Inc.